Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Assets: 2012-2025

Historic Current Assets for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $204.3 million.

  • Enanta Pharmaceuticals' Current Assets fell 31.85% to $204.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $204.3 million, marking a year-over-year decrease of 31.85%. This contributed to the annual value of $204.3 million for FY2025, which is 31.85% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Current Assets of $204.3 million as of Q3 2025, which was down 8.25% from $222.7 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Current Assets' 5-year high stood at $448.5 million during Q2 2023, with a 5-year trough of $204.3 million in Q3 2025.
  • In the last 3 years, Enanta Pharmaceuticals' Current Assets had a median value of $286.6 million in 2024 and averaged $309.8 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Current Assets surged by 43.26% in 2023, and later tumbled by 36.10% in 2024.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Current Assets stood at $327.0 million in 2021, then decreased by 13.23% to $283.7 million in 2022, then surged by 37.57% to $390.3 million in 2023, then crashed by 31.30% to $268.1 million in 2024, then crashed by 31.85% to $204.3 million in 2025.
  • Its last three reported values are $204.3 million in Q3 2025, $222.7 million for Q2 2025, and $242.9 million during Q1 2025.